Tu Youyou

Tu Youyou was born on December 30, 1930, in Ningbo, a coastal city in Zhejiang Province known for its mercantile traditions and scholarly culture. Her given name, Youyou, derives from the ancient poetry collection *Shi Jing* (Classic of Poetry), specifically a verse that reads 'Youyou lu ming' — 'the deer cry out yearningly.' The line continues with references to wormwood, a botanical detail that would later take on extraordinary significance in her scientific career. She grew up during a tumultuous period of Japanese occupation and civil war, experiences that shaped her generation's commitment to national reconstruction through science and service.

At age sixteen, Tu contracted tuberculosis and was forced to interrupt her schooling for two years. The illness left a lasting impression. She witnessed firsthand the limitations of available treatments and the suffering caused by infectious disease. This formative experience influenced her decision to pursue medicine. In 1951, she enrolled in the Department of Pharmaceutical Sciences at Peking University Medical School (now Peking University Health Science Center). She graduated in 1955 and was assigned to work at the China Academy of Traditional Chinese Medicine (now the China Academy of Chinese Medical Sciences) in Beijing, where she would remain for the duration of her career. Notably, Tu never pursued a doctoral degree and never studied abroad, a fact that later became emblematic of her unconventional path to global scientific recognition.

Tu's early research focused on integrating traditional Chinese medicine with modern pharmacology. In the 1960s, she received training in traditional Chinese medical texts and practices, an unusual hybrid education that would prove essential to her later breakthrough. The opportunity that defined her career came in 1969, when she was recruited to join Project 523, a secret military research initiative. The project's name derived from its start date—May 23, 1967—and its purpose was to discover new treatments for malaria, which was devastating Chinese troops supporting North Vietnam and causing widespread civilian casualties.

Malaria parasites had developed resistance to chloroquine and other standard drugs. The urgency was immense. Tu was appointed head of the research group at her institute, despite being a relatively junior researcher. What set her apart was her methodological approach: rather than starting with modern chemistry, she systematically reviewed ancient medical texts. Over several years, her team compiled more than 2,000 traditional herbal recipes. From this archive, they selected 640 for laboratory testing. Most showed no meaningful antimalarial activity.

The breakthrough came when Tu examined *A Handbook of Prescriptions for Emergencies*, written by Ge Hong in 340 CE. One entry described using qinghao (sweet wormwood, *Artemisia annua*) steeped in water to treat intermittent fevers characteristic of malaria. Initial modern extracts using boiling water failed. Tu hypothesized that high temperatures might be destroying the active ingredient. In October 1971, she tested a low-temperature ether extraction method. Extract number 191 showed 100 percent effectiveness against malaria parasites in rodent models. The discovery was confirmed in monkey trials.

Demonstrating extraordinary personal courage, Tu and two colleagues volunteered to be the first human subjects, testing the extract on themselves to ensure safety before clinical trials expanded to malaria patients. The trials, conducted in Hainan Province in 1972, showed remarkable efficacy. By 1977, Tu and her collaborators had isolated and characterized the active compound, which they named qinghaosu—later known internationally as artemisinin. The molecular structure revealed a unique sesquiterpene lactone with an unusual peroxide bridge, the source of its antimalarial power.

Artemisinin and its derivatives have transformed malaria treatment globally. Unlike earlier drugs that targeted the malaria parasite's food vacuole, artemisinin acts rapidly across multiple stages of the parasite's life cycle, clearing infections within days rather than weeks. This speed is critical in severe cases. Artemisinin-based combination therapies (ACTs)—which pair artemisinin derivatives with longer-acting partner drugs to prevent resistance—became the World Health Organization's recommended first-line treatment for Plasmodium falciparum malaria in the early 2000s.

According to WHO estimates, malaria deaths fell by more than 50 percent between 2000 and 2015, dropping from approximately 840,000 to 430,000 annually. While this decline resulted from multiple interventions including insecticide-treated bed nets and improved diagnostics, ACTs were central to treatment success. The Lancet estimated in 2015 that artemisinin-based therapies had saved millions of lives, particularly in sub-Saharan Africa where malaria burden is heaviest. Beyond saving lives, artemisinin reduced the duration and severity of illness, lessening the economic burden on impoverished communities.

Tu's work also demonstrated the value of traditional knowledge as a starting point for modern drug discovery. Her methodology—systematic review of historical texts, careful extraction of candidate compounds, and rigorous testing—offered a replicable model. She showed that traditional medicine and modern pharmacology need not be opposing paradigms but can be mutually reinforcing when approached with scientific discipline. This insight has encouraged bioprospecting efforts and renewed interest in ethnobotanical research worldwide.

For decades, Tu's achievement received limited recognition outside China, and even domestically, credit was often attributed to collective research teams rather than individuals—a reflection of China's political culture during the Mao era. She did not publish her findings in international journals until the 1980s, and language barriers, combined with China's relative scientific isolation, delayed global awareness of her contribution. It was not until 2011 that Tu began receiving major international awards, beginning with the Lasker-DeBakey Clinical Medical Research Award, often called 'America's Nobel.'

The 2015 Nobel Prize in Physiology or Medicine, shared with William C. Campbell and Satoshi Ōmura for discoveries concerning therapies against parasitic infections, brought Tu global recognition. At age 84, she became the first mainland Chinese scientist and the first Chinese woman to receive a Nobel Prize in the sciences. The Nobel Committee specifically cited her use of traditional Chinese medicine to develop artemisinin. In her Nobel Lecture, Tu emphasized the collaborative nature of the research and honored her colleagues from Project 523, many of whom had passed away without recognition.

Tu also received China's first State Preeminent Science and Technology Award in 2016, the nation's highest scientific honor, accompanied by a monetary prize of five million yuan. She has been awarded honorary doctorates and medals from institutions worldwide, though she has largely remained reticent in public life, preferring her laboratory work to ceremony.

Tu Youyou's legacy operates on multiple levels. Most immediately, artemisinin continues to save lives. Despite emerging concerns about parasite resistance in the Greater Mekong Subregion—a challenge Tu herself has warned about—ACTs remain the most effective malaria treatments available. Her discovery bought the world crucial decades in the fight against a disease that still infected 241 million people in 2020. Ongoing research into artemisinin derivatives and combination strategies builds directly on her foundational work.

Beyond pharmacology, Tu challenged assumptions about the sources of innovation. She demonstrated that valuable knowledge exists outside the conventional institutions of Western science and that successful researchers need not follow traditional academic pathways of doctoral degrees and overseas fellowships. Her success has inspired a generation of Chinese scientists and contributed to the country's growing confidence in its indigenous research capacity. She became a symbol of how dedication, creativity, and methodological rigor can overcome institutional limitations.

Tu's approach to traditional medicine also offers a nuanced middle path in ongoing debates about alternative and complementary therapies. She neither dismissed traditional knowledge as superstition nor accepted it uncritically. Instead, she treated historical texts as hypotheses requiring experimental validation. This evidence-based approach to traditional medicine has influenced research policies in China and other countries with rich ethnobotanical traditions, encouraging systematic investigation rather than blanket acceptance or rejection.

Her story resonates particularly in discussions about women in science. Working in an era when Chinese women faced systemic barriers to advancement, often balancing research with family responsibilities during politically turbulent times, Tu persevered. She never sought the spotlight, yet her eventual recognition at age 84 sent a powerful message about the enduring value of rigorous scientific work, regardless of when or by whom it is acknowledged. For young scientists, particularly women in developing countries, her trajectory offers both inspiration and a reminder that meaningful contributions may take decades to receive their due recognition—but remain meaningful nonetheless.